What's Happening

Stay up to date on conferences, social posts, and what’s new with Healthesystems

Events

Let’s connect at one of our upcoming conferences or speaking engagements
October 15 - Oct 17, 2024

National Comp Conference

Healthesystems is exhibiting and speaking at National Comp, the largest annual gathering of workers’ compensation leaders in the country.

Las Vegas, NV
View all Events

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Otulfi™ (ustekinumab-aauz)

Approval Date: Sep 2024

Note: New Product

A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

hello world!

Zurnai® (nalmefene injection)

Approval Date: Aug 2024

Note: New Product

An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.

hello world!

Neffy® (epinephrine nasal spray)

Approval Date: Aug 2024

Note: New Product

Indicated for the emergency treatment of type I allergic reactions, including anaphylaxis

hello world!

Tezruly™ (terazosin) oral solution

Approval Date: Jul 2024

Note: New Product

Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate

hello world!

Zunveyl (benzgalantamine) delayed-release tablets

Approval Date: Jul 2024

Note: New Product

Indicated for the treatment of mild to moderate dementia of the Alzheimer's type

hello world!

Olumiant (baricitinib) tablets

Approval Date: Jul 2024

Note: First-Time Generic

Indicated for the treatment of moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers

hello world!

Kisunla (donanemab-azbt) injection

Approval Date: Jul 2024

Note: New Product

Indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patient with mild cognitive impairment or mild dementia stage of disease, the population in which the treatment was initiated in the clinical trials

hello world!

Qsymia® (phentermine and topiramate) extended-release tablets

Approval Date: Jun 2024

Note: First-Time Generic

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management

hello world!

Stendra® (avanafil) tablets

Approval Date: Jun 2024

Note: First-Time Generic

Indicated for the treatment of erectile dysfunction

hello world!

Pyzchiva® (Ustekinumab-ttwe) injection

Approval Date: Jun 2024

Note: Biosimilar

A biosimilar to Stelara; indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis

hello world!
1 2 3 14

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmagnifiermenucross-circle